‘World-First’ AI-Designed Vaccine Enters Human Trial, Aiming to Protect Against Future Pandemic Threats
Advertisement
Researchers are now preparing a larger Phase 2 trial involving approximately 200 participants to further evaluate immune responses and broader effectiveness.
A team of researchers from the University of Cambridge has reported the first successful human trial of a vaccine whose key antigen was created entirely using artificial intelligence, strengthening preparedness for future pandemics.
The artificial intelligence-designed vaccine targets multiple coronaviruses simultaneously, including current COVID-19 variants and related viruses circulating in animals that could trigger future outbreaks.
Instead of focusing on a single virus strain, the Cambridge-led team used artificial intelligence to analyze genetic data collected from numerous coronaviruses identified through global surveillance programs.
The AI system then designed a "super-antigen," the active component of the vaccine, that combines common characteristics shared across different viruses. The goal is to train the immune system to recognize and respond to a much wider range of threats, including viruses that have not yet emerged in humans.
According to Professor Jonathan Heeney of the University of Cambridge, the approach represents a shift from responding to outbreaks after they occur toward anticipating future viral threats.
He said, "This is about making vaccines that protect us, not just from today's viruses, but also protect us from what can cause the next outbreak or disease."
The first clinical trial enrolled 39 volunteers between 2021 and 2023 and was primarily designed to evaluate safety and tolerability. Researchers reported no major safety concerns across multiple dose levels.
Findings published in the Journal of Infection indicated that while the immune response observed was modest, the results support further development and larger-scale testing.
Professor Saul Faust, who led parts of the trial at the University of Southampton, highlighted the potential advantages of AI-assisted vaccine design for rapidly evolving pathogens.
He said, "What's really interesting is that the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing."
Researchers are now preparing a larger Phase 2 trial involving approximately 200 participants to further evaluate immune responses and broader effectiveness.
Beyond coronaviruses, the team is applying the same artificial intelligence platform to develop vaccines targeting influenza, H5N1 bird flu, Ebola, and other viral diseases with pandemic potential.
Stay tuned for more such updates on Digital Health News
